Inhibiting MEK Protein Shrinks NF1 Plexiform Tumors After five other medications fail, selumetinib becomes first to demonstrate lasting improvement. In some ways, the impressive results from a clinical trial published in The New England Journal of Medicine mark the triumph of a scientific career.
Read Featured Research| Research and Training Details | |
|---|---|
| Faculty | 26 |
| Joint Appointment Faculty | 3 |
| Research Fellows and Post Docs | 6 |
| Research Graduate Students | 4 |
| Total Annual Grant Award Dollars | $2,428,147 |
| Total Annual Industry Award Dollars | $851,654 |
| Clinical Activities and Training | |
|---|---|
| Staff Physicians | 8 |
| Clinical Fellows | 8 |
| Inpatient Encounters | 1,266 |
| Outpatient Encounters | 14,793 |